Sashwath Srikanth
Louis DeVito
Nicholas J. Constantinesco
Radha Gopal- Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, United States
Cardiovascular diseases (CVD) are increasingly recognized as an outcome of multiple inflammatory processes. Despite a large recent research focus, the majority of attempts to therapeutically target chemokines, have not been successful. Thus, a better understanding of the mechanisms involving chemokines contributing to CVD is warranted to identify the missing gaps in the field. This review summarizes the latest developments on the role of chemokines in the pathogenesis of atherosclerosis, heart failure (HF), coronary artery disease, myocarditis, cardiomyopathy, and arrhythmias. We also aim to provide insight into the current clinical trials and potential therapeutics targeting chemokines and their receptors.
Introduction
Chemokines are molecules that play a pivotal role in the process of inflammation. Chemokines are essentially low molecular weight chemotactic cytokines (8–10 kd) with 20–70 percent homology (1). Based on the relative position of their cysteine residues, they are classified into four families (C, CC, CXC, CX3C) (2, 3). Out of the four families, the two families (α and β) that have four cysteine residues have been extensively studied. In the α family the first two cysteine residues are separated by an amino acid (CXC) whereas in the β family, the two cysteine residues are adjacent to each other (CC). Fractalkine is another family where there are three amino acids in between the two cysteine residues (CX3C) (4). The fourth family consists of lymphotactin which contains only one disulfide bond (5, 6). The α family can further be divided into those that have and do not have the glutamic acid-leucine-arginine sequence near the N-terminal, prior to the CXC sequence (7). Those that have this sequence play a role in neutrophil chemotaxis (1). Those α-chemokines that do not have this sequence play a role in lymphocyte chemotaxis (8, 9). The β-chemokines can be further sub-divided into two groups: monocyte-chemoattractant protein and eotaxin groups (10). Although most chemokines in the β family contain four cysteines, some of them contain six cysteine residues (C6-CC) (11, 12).
Chemokine receptors are G protein-coupled receptors that have seven transmembrane domains. These receptors interact with specific chemokine ligands and induce a calcium influx. This causes a cellular response that results in chemotaxis of leucocytes. So far 20 different chemokine receptors have been identified in humans. The activation of chemokine receptors on leucocytes has been shown to lead to proliferation, survival, differentiation, cytokine production, degranulation, and respiratory burst (13, 14) (Table 1). Recent work has broadened our understanding of the functional versatility and robustness of the chemokine network and its role in the pathogenesis of various diseases.
Table 1. Chemokines and their receptor functions.
Cardiovascular disease (CVD) is one of the most common causes of mortality in developed countries. About 655,000 Americans die from heart disease each year – that’s one in every 4 deaths (15). Chemokines play a role in CVDs such as atherosclerosis, coronary artery disease, heart failure, arrhythmias, and myocarditis. The role of chemokines and their receptors in these diseases will be reviewed herein, with a particular focus on the pathogenic mechanism involved in these diseases. We further explored the therapeutic potential of targeting chemokines on CVD.
Chemokines and their receptors in atherosclerosis
Atherosclerosis initiation
Atherosclerosis is one of the major causes of CVD including myocardial infarction, stroke, and heart failure. It is a well-known fact that the process of atherosclerosis starts with chronic endothelial damage. This leads to endothelial dysfunction where there is an increased permeability of the endothelial layer. Lipids, especially low density lipoprotein, infiltrate the endothelium and accumulate in the intimal layer of the artery (16). The trapped LDL in the sub-endothelial (intimal) layer of the artery is prone to oxidization and forms oxidized LDL (ox-LDL) (17). Ox-LDL activates macrophages and endothelial cells and gets taken up by macrophages where they get hydrolyzed into free fatty acids and cholesterol (18). However, the free cholesterol undergoes re-esterification and forms cholesteryl esters (19). Macrophages, unable to excrete these esters transform into foam cells, which is one of the first changes noticed in atherosclerosis. Studies have shown that CC and CXC type of chemokines play a role in atherosclerosis initiation.
Endothelial cells, upon activation by ox-LDL, release a variety of chemokines that recruit neutrophils and monocytes to the sub-endothelium and the formation of foam cells that initiate plaque growth (20–25) (Figure 1). Schober et al. showed that there is an up-regulation of CCL2 in serum and the vessel wall when there is injury to the carotid artery in apolipoprotein E deficient (ApoE-/-) mice (26). Monocytes of the classical type (Ly6Chigh) migrate towards the atherosclerotic lesion. One of the key chemokines that attract these monocytes is CCL2. Recently, the CCL2-CCR2 axis has been examined as a drug target for atherosclerosis because of this chemotactic property (27). CCL3 acts through CCR1 and CCR5 and increases the recruitment of neutrophils, thus increasing atherosclerosis (28). CCL4-CCR5 interactions increase endothelial and macrophage cell activation, thereby increasing plaque formation (29). CCR1/5 cause recruitment of monocytes and other circulating cells (30). CCL5 allows for leukocyte attraction to the damaged vascular endothelium, which again causes inflammation (31). CXCL1 and CXCL2 recruit neutrophils and monocytes to the site of inflammation via the receptor CXCR2 (32–36). Studies have shown that a reduction in CXCL1 levels can reduce inflammation and plaque formation (33). CXCL8 is involved in recruitment of neutrophils and monocytes to the endothelium through CXCR2. Studies have shown that 27-oxygenated cholesterol induces CXCL8 in macrophages (37). CX3CL1 has been shown to be involved in macrophage infiltration and lesion formation (38). Classical Ly6Chi monocytes depend on CCR2 or CX3CR1 to enter into atherosclerotic plaques (39). Another study has shown that CCR1 and CCR5 receptors play a role in mediating monocyte infiltration in atherosclerosis (33). Overall, these studies show the chemokines and the receptors are involved in atherosclerosis initiation by recruiting leukocytes to the sub-endothelium thereby enhancing lesion progression (Figure 1).
Figure 1. Chemokines and their receptors in atherosclerosis. (a) Atherosclerosis disease process is initiated by endothelial dysfunction and accumulation of low-density lipoprotein (LDL) in the sub-endothelial space. LDL is oxidized, and Ox-LDL stimulates the vascular endothelium to increase adhesion molecules, and chemokines such as CCL2, CCL5, CXCL1, and CX3CL1. These chemokines act through the respective receptors and recruit monocytes, neutrophils, and lymphocytes in the sub-endothelium. Macrophages increase the expression of scavenger receptors, engulf ox-LDL, and become foam cells. CX3CL1 acts through CX3CR1 and increases foam cell formation. Over time, foam cells undergo apoptosis and necrosis, thus leading to the accumulation of cell debris and the formation of a necrotic core within the intima. Smooth muscle cells then synthesize collagen and elastin, which form the fibrous cap that covers the necrotic core. If the fibrous cap is fragile, it may rupture and cause coronary artery disease, including MI, stroke, and heart failure. CCL4 and CXCL10 increase plaque instability that increases thrombosis. CCL17 and CCL22 induce platelet activation through their CCR4 receptor. (b) Chemokines CCL2, CCL3, CXCL9, CXCL10 and CX3CR1 recruit monocytes, macrophages and neutrophils in myocarditis. (c) Chemokines CCL2, CCL3, CXCL8, and CXCL9 drives cellular infiltration, iron channel dysfunction and fibroblast activation in arrhythmia. (d4) Chemokines CCL2, CXCL1, CXCL5, CX3CR1 recruit inflammatory monocytes and neutrophils into the injured ventricle, induce fibrosis and structural remodeling in heart failure.
Bacterial and viral infection increases atherosclerosis by directly infecting vascular cells or indirectly increasing inflammatory cytokines and chemokines systemically. Studies have shown that the Chlamydia pneumoniae increases CCL2 systemically in HFD-induced atherosclerosis (40). Also, We and others have shown that the influenza infection increases CCL2, CCL3 and CCL5 in the aorta and the serum in Apoe-/- mice (41, 42). These studies suggest that chemokine induction during the infection may be involved in infection-induced exacerbation of atherosclerosis. However, the specific role of these chemokines in infection-induced exacerbation of atherosclerosis is not clear.
Atherosclerosis progression and regression
As more lipids and debris continue to accumulate, the imbalance between the apoptosis and efferocytosis of macrophages leads to formation of a necrotic core (43–46). Chemokines have been shown to play a role in these processes. Increased apoptosis of monocytes and foam cells were observed in CX3CR1-deficient mice suggesting that CX3CR1 has a role in cell survival, thereby increasing plaque formation (47). In advanced plaques, fibroblast−activating chemokines such as CCL2, CCL5, CXCL10, and CXCL12 contributing to collagen deposition and fibrous tissue formation (48–50). Rupture of the fibrous cap leads to accelerated thrombosis leading to occlusion of the blood vessel and results in a cardiovascular event. Thus, the thickness of the fibrous cap is crucial for plaque stability. It has been shown that inhibition of CXCL10 leads to stable atherosclerotic plaques suggesting that CXCL10 is involved in plaque destabilization (50). Further, a study has shown that the CXCL10 increases atherosclerosis by modulating balance between Treg and effector T cells, locally (51). Another study has shown that CCL4 antibody treatment increases fibrous cap thickness suggesting that CCL4 is involved in unstable plaque formation (29). Recently it has been shown that CCL2 is a biomarker for plaque instability in patients who underwent carotid endarterectomy (52). As discussed above, a plaque rupture causes an accelerated thrombus formation, and platelets play a crucial role in this process. CCL17 and CCL22 have been shown to induce platelet activation through the CCR4 receptor (53, 54). CXCL12 induces platelet activation and aggregation through CXCR4 expressed on platelets (48). Moreover, migration and transmigration of platelets have been observed to be stimulated by CXCL12 (55). Chemokines are also involved in atherosclerotic plaque regression by immune cell egress, resulting in resolution and tissue remodeling. Trogan et al. showed that CCR7 has a functional significance in atherosclerosis regression. The authors also noticed that regression of the atherosclerotic lesion is inhibited by treatment with antibodies to CCR7 ligands CCL19 and CCL21 (56). Another study has shown that inhibition of CXCL1-CXCR2 and CX3CL1-CX3CR1 axis affected endothelial progenitor cell-mediated atherosclerosis regression (57). The abundance of chemokines involved in atherosclerosis corresponds to the functional complexity of pathogenesis.
Chemokines and their receptors in coronary artery disease
Coronary artery disease (CAD), a key outcome of atherosclerosis, causes significant morbidity and mortality in populations around the world. While much is yet to be discovered, CCL2, CCL5, CXCL1, and CXCL12 are found to be involved in CAD (58–62). A study by Luciano-Mateo et al. has demonstrated that autopsy reports of recently deceased individuals from CAD had a higher level of CCL2 in their serum (63). Although they caution that their finding may not be representative and that it is just an observational study, there has been another study done by Li et al. that continues to build upon that report. They have shown that circulating CCL2 serum levels correlated with an increase in the risk of CAD (58, 59). CCL5-polymorphism has been linked to an increased risk of CAD (59, 64). While this shows a pathogenic role of CCL5 in CAD, there are contradicting reports from Gencer et al. that state CCL5 is responsible for halting immune cell function and infiltration, leading to reduced plaque formation and induction of CAD (61). CXCL1 is shown to be involved in recruiting macrophages and lesion progression (38). A study has shown that the gene expression of CXCL1 was increased in PBMCs from CAD patients when compared to the healthy controls (65). CXCL12 attracts immune cells and stem cells to wounded vascular endothelial cells (59, 61, 66). High levels of this chemokine are associated with CAD (66). While more research is necessary to better understand the roles that chemokines play during CAD, it is important to note that chemokine attraction of immune cells to the site of the vascular endothelium play a major role in plaque formation and thereby CAD.
Chemokines and their receptors in heart failure
Heart failure is characterized by dyspnea, poor exercise tolerance, fatigue, and fluid retention caused by cardiac dysfunction. Heart failure (HF) affects 6.2 million American adults and projections estimate about 8 million adults will be affected by HF by 2030 (15, 67). Studies such as the RELAX, TIME-CHF, and ASCEND-HF trials have consistently shown the high prevalence of inflammation in heart failure (68–70). Chemokines, being a major player in the immune system, have been demonstrated to be consistently elevated in heart failure (71, 72) (Figure 1). Heart failure is classified based on reduced (HFrEF) or preserved (HFpEF) ejection fraction. In HFrEF, chemokine activation is driven primarily by myocardial injury, necrosis, and adverse remodeling especially early post-MI or primary cardiomyopathies, producing a surge in CCL2–CCR2, CCL5-CCR5, CX3CL1–CX3CR1, and CXCL8–CXCR2 signaling that recruits inflammatory monocytes and neutrophils into the injured ventricle (73–75). In contrast, HFpEF is characterized by systemic metabolic inflammation and microvascular dysfunction, where chemokines such as CCL2, CCL5, CXCL5, and CX3CL1 originate largely from adipose tissue, vascular endothelium, and perivascular macrophages rather than necrotic myocardium. While both phenotypes share chronic activation of monocyte/macrophage−related axes (e.g., CCL2–CCR2, CCL5-CCR5, and CX3CL1–CX3CR1), HFrEF exhibits acute, injury−centric chemokine induction, whereas HFpEF displays persistent, low−grade, metabolically primed chemokine signaling (76–78). Studies have shown that CCL2 has been expressed in both HFrEF and HFpEF and the proinflammatory role of CCL2 leading to adverse remodeling and cardiac dysfunction (79–81). In heart failure patients with reduced EF, increased CCL2 levels correlated with worsening of symptoms and poor systolic dysfunction (73). This finding was backed by Aukrust et al. whose study showed that CCL2 levels were inversely correlated with left ventricular EF (82). Moreover, higher CCL2 levels were linked to higher mortality rates in patients with advanced heart failure (83). CCL5 plays a notable role in the inflammatory processes in both HFrEF and HFpE. Inhibition of CCL5 led to improved cardiac function and survival in post-MI cardiac failure murine models (74). Similarly, in the ischemia/reperfusion murine models, intraperitoneal injections with CCL5 antagonists resulted in less oxidative stress and decreased cardiomyocyte death (84). CXCL1, CXCL5, and CXCL8 were increased in patients with congestive heart failure in a study conducted by Damas et al. (79). Recent study has shown that heart failure-specific fibroblasts contribute to the heart failure through a CXCL1-CRCR2 axis (85). With chemokines playing such a central role in the development and progression of heart failure, targeting these chemokines could impact the lives of millions worldwide.
Chemokines and their receptors in arrhythmias
The heart contracts in a synchronized manner which is coordinated by a complex electrical system within the heart tissue. Normal sinus rhythm originates from the SA node and propagates via the His-Purkinje system to depolarize the ventricles in a systematic way to cause controlled muscle contractions. A disruption or irregularity in this electromechanical system leads to an arrhythmia. The heart is highly innervated by the autonomic nervous system (ANS) and the connection between the ANS and arrhythmias is well established. Chemokine signaling alters autonomic tone by driving inflammation, sympathetic hyperinnervation, and vagal suppression. This imbalance destabilizes cardiac electrophysiology, making arrhythmias more likely and more severe (Figure 1). A recent study has shown that increased resistin-like molecule gamma (RELMγ) from neutrophils attacks cardiomyocytes which causes ventricular tachycardia (86). Furthermore, a meta-analysis conducted by Wu et al. evidenced that patients with increased levels of inflammatory mediators were at higher risk of developing atrial fibrillation (AF) than the general population (87). CCL3 has been shown to stimulates the nervous system during antigenic challenge (88). Elmas et al. showed that the levels of CXCL8 and TIMP1 were significantly higher in MI patients with ventricular fibrillation (VF) as compared to those without VF (89). Also, CXCL8, CCL2, CCL4, and other pro-inflammatory mediators were found to be elevated in patients with arrhythmogenic right ventricular dysplasia (ARVD) as compared to controls (90). It is interesting to note that CXCL8 levels were higher in patients with permanent AF than in those with paroxysmal AF (91). CXCL9 was also found to have a direct impact on cardiomyocyte action potential duration and electrical stability of the heart (92). CXCR2 was shown to be involved in atrial fibrillation by driving monocyte infiltration (93). Thus, targeting these chemokines and their receptors could help to reduce the stimulation of the ANS which in turn reduce arrhythmia.
Chemokines and their receptors in myocarditis
Myocarditis is characterized by inflammation of the heart muscle and is said to be caused by various infectious and non-infectious etiologies (94) (Figure 1). Among the infectious etiologies, viruses are presumed to be the most common pathogen. Viral myocarditis is acute onset and may resolve in response to viral clearance or progress to dilated cardiomyopathy. Some of the common causes of viral myocarditis include influenza A and B viruses, enteroviruses (coxsackie A and B), viruses of the Herpesviridae family, parvovirus B-19, adenoviruses, MERS-CoV, SARS-CoV, SARS-CoV-2, HIV, and hepatitis C virus (95). Viruses directly infect cardiomyocytes and activate TLR/RIG-I signaling pathways thereby increasing inflammatory mediators. Chemokines recruit neutrophils, monocytes and NK cells to clear the virus (95–97). CCL2 was also shown to be significantly elevated in mice with Coxsackievirus B3 (CVB3) induced myocarditis (98). From our studies, we have shown that the influenza infection increases CCL2, CCL3, CXCL9 and CXCL10 in the heart (99). Autoimmune disorders are also able to cause myocarditis due to chronic and progressive inflammation. Some of the autoimmune disorders that can cause myocarditis are systemic lupus erythematosus, systemic sclerosis, sarcoidosis, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, inflammatory myopathies, rheumatoid arthritis, myasthenia gravis, and autoinflammatory diseases (100). Autoantibodies against cardiac proteins, autoreactive T cells, and chemokine-mediated chronic inflammation are the primary mechanisms involved in auto-immune myocarditis (101). Studies in murine models of experimental autoimmune myocarditis (EAM) showed upregulation of CCL2 (102, 103). Blocking CCL2 with monoclonal antibodies resulted in reduced severity of autoimmune myocarditis (102). A study by Leuschner et al. revealed that siRNA silencing of CCR2 (siCCR2) led to reduced leukocyte progenitor trafficking in autoimmune myocarditis (104). These studies suggest that targeting these chemokines and their respective receptors may be beneficial for myocarditis. However, recently detrimental effects of CCL17 deletion have been shown in viral myocarditis via suppression of regulatory T cells (105).
Overall, a small set of shared chemokine axes, particularly CCL2–CCR2, CCL5–CCR5, and CX3CL1–CX3CR1 form a common inflammatory and vascular framework across atherosclerosis, myocarditis, heart failure, and arrhythmia. These pathways are involved in monocyte recruitment, endothelial activation, and fibroblast remodeling, but each disease engages them in distinct tissue contexts. Atherosclerosis uses these axes to drive leukocyte accumulation and smooth muscle activation; myocarditis amplifies monocyte and T cell infiltration; heart failure repurposes them for post−injury inflammation or metabolic–microvascular dysfunction; and arrhythmias emerge when chronic chemokine signaling remodels atrial or ventricular substrate. However, some chemokines play specific role based on the disease. In atherosclerosis, CCL19/21- CCR7 axis play a role in plaque regression (56). Similarly, in myocarditis, the presence of CCL17 is shown to be beneficial (105). Collectively, these studies suggest that the chemokines play both shared versus disease specific roles in cardiovascular diseases.
Targeting chemokines and their receptors in cardiovascular diseases
Studies have shown that CCL2 plays an extensive role in cardiac remodeling and dysfunction. Targeted antagonism of the CCL2:CCR2 axis may prove to be promising in heart failure therapy. MLN1202, which is an anti-CCR2 monoclonal antibody, significantly reduced C-reactive protein (CRP) levels. As we know, CRP is a biomarker used to classify patients at high risk for atherosclerosis. However, the direct association between MLN1202 and adverse cardiovascular events are not yet studied (106). A meta-analysis of pre-clinical studies shown that targeting CCL2: CCR2 axis resulted in reduction in atherosclerosis lesion formation (107). Bindarit, which inhibits the expression of CCL2, CCL7, CCL8 and IL-12, significantly reduced in-stent late loss in CAD patients who underwent a PCI, but had no effect on the major adverse cardiovascular outcomes (108).
The interactions of CCL5 with CXCL4, CCL17, and HNP1 present interesting therapeutic targets. Rationally designed synthetic peptides, termed MKEY, CAN, and SKY were implemented to block the interactions of CCL5 with CXCL4, CCL17, and HNP1, respectively. This resulted in a reduction of atherosclerotic plaque size and a reduced ischemia-reperfusion injury in mice treated with the respective peptides. These examples illustrate that interactions of CCL5 with other proteins might be an interesting approach for the treatment of CVD, with less risk for immunologic side effects as a total functional blockade of CCL5 (109). Maraviroc, a CCR5 antagonist, is a common medication used in HIV patients. Patients with HIV are at an increased risk of developing atherosclerosis and unsurprisingly, it has been considered for the prevention of atherosclerosis. In mice, Maraviroc successfully reduced atherosclerotic plaque development (110). It is currently undergoing a Phase IV trial to study the effect of CCR5 antagonism on atherosclerosis in HIV patients. POL6326, a CXCR4 antagonist, is currently in a phase II trial on the effect on heart function and infarct size in patients who underwent reperfusion after an ST Elevation Myocardial Infarction (STEMI). In the phase II STOP-HF trial, a single endocardial dosing of CXCL12 coding plasmid (JVS-100) improved cardiac function at 12 months after treatment in patients with left ventricular ejection fraction (EF) <26% post MI (111).
Despite strong evidence showing promising results targeting chemokines in cardiovascular diseases, a major barrier is the redundancy within the chemokine system. Multiple ligands signal through the same receptor, and many receptors respond to several ligands, allowing inflammatory recruitment to persist even when a single axis is blocked. In parallel, compensatory signaling rapidly restores leukocyte trafficking through alternative pathways including upregulation of CX3CL1–CX3CR1 or CCL5–CCR5 axis when CCR2 is inhibited—preserving inflammatory response within the myocardium or vasculature. A further limitation of current chemokine-based therapies is that the field has only recently begun to explore cell-targeted delivery strategies, such as nanoparticle-mediated monocyte targeting and ligand-directed approaches. Addressing these barriers will be essential for designing next-generation chemokine-directed therapies in cardiovascular diseases.
Conclusion
Chemokines play a role in cardiovascular diseases by recruiting immune cells to the sub-endothelium influencing plaque stability, plaque progression, adverse remodeling, and cardiac dysfunction in heart failure, arrhythmias, and myocarditis. The pathophysiologic heterogeneity of these diseases is a major barrier that hinders the development of new therapeutics. For example, patients with diabetes mellitus or chronic kidney disease have an increased risk of CVD, partly caused by increased and altered inflammatory processes in these patients. Unravelling comorbidity-associated alterations is essential for successful clinical translation in defined patient groups, supporting more personalized treatment approaches. Similarly, infection induced inflammation increases the outcome of the disease severity. Inhibiting the immunological function of these proteins may also be detrimental. Most studies have focused on suppressing inflammation rather than promoting its active resolution, a biologically distinct process mediated by specialized pro-resolving mediators, macrophage reprogramming, and coordinated clearance of inflammatory cells. Failure to distinguish suppression of inflammation from resolution can impact necessary repair responses or incompletely extinguish chronic inflammation. Therefore, specific treatment approaches are required to tackle these issues in developing chemokine-based therapeutics in cardiovascular diseases.
Author contributions
SS: Writing – review & editing, Writing – original draft, Investigation, Conceptualization. LD: Conceptualization, Writing – review & editing, Writing – original draft, Investigation. NC: Writing – original draft, Investigation, Writing – review & editing, Conceptualization. RG: Funding acquisition, Conceptualization, Validation, Writing – review & editing, Investigation, Supervision.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by funding from NHLBI R01 HL146479 (RG).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Luster AD. Chemokines–chemotactic cytokines that mediate inflammation. N Engl J Med. (1998) 338:436–45. doi: 10.1056/NEJM199802123380706
2. Baggiolini M, Dewald B, and Moser B. Interleukin-8 and related chemotactic cytokines–CXC and CC chemokines. Adv Immunol. (1994) 55:97–179.
3. Baggiolini M, Dewald B, and Moser B. Human chemokines: an update. Annu Rev Immunol. (1997) 15:675–705. doi: 10.1146/annurev.immunol.15.1.675
4. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. (1997) 385:640–4.
5. Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science. (1994) 266:1395–9. doi: 10.1126/science.7973732
6. Kelner GS and Zlotnik A. Cytokine production profile of early thymocytes and the characterization of a new class of chemokine. J Leukoc Biol. (1995) 57:778–81. doi: 10.1002/jlb.57.5.778
7. Clark-Lewis I, Schumacher C, Baggiolini M, and Moser B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem. (1991) 266:23128–34. doi: 10.1016/S0021-9258(18)54472-0
8. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, and Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. (1996) 184:1101–9. doi: 10.1084/jem.184.3.1101
9. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. (1996) 184:963–9. doi: 10.1084/jem.184.3.963
10. Luster AD and Rothenberg ME. Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. J Leukoc Biol. (1997) 62:620–33. doi: 10.1002/jlb.62.5.620
11. Laing KJ and Secombes CJ. Chemokines. Dev Comp Immunol. (2004) 28:443–60. doi: 10.1016/j.dci.2003.09.006
13. Allen SJ, Crown SE, and Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. (2007) 25:787–820. doi: 10.1146/annurev.immunol.24.021605.090529
14. López-Cotarelo P, Gómez-Moreira C, Criado-García O, Sánchez L, and Rodríguez-Fernández JL. Beyond chemoattraction: multifunctionality of chemokine receptors in leukocytes. Trends Immunol. (2017) 38:927–41. doi: 10.1016/j.it.2017.08.004
15. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: A report from the american heart association. Circulation. (2020) 141:e139–596. doi: 10.1161/CIR.0000000000000757
16. Williams KJ and Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. (1995) 15:551–61. doi: 10.1161/01.ATV.15.5.551
17. Hansson GK and Hermansson A. The immune system in atherosclerosis. Nat Immunol. (2011) 12:204–12. doi: 10.1038/ni.2001
18. Plüddemann A, Neyen C, and Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods. (2007) 43:207–17.
19. Brown MS, Ho YK, and Goldstein JL. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem. (1980) 255:9344–52. doi: 10.1016/S0021-9258(19)70568-7
21. Boring L, Gosling J, Cleary M, and Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. (1998) 394:894–7.
22. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. (1998) 2:275–81. doi: 10.1016/S1097-2765(00)80139-2
23. Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, Inoue S, et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation. (2001) 103:2096–101.
24. Dawson TC, Kuziel WA, Osahar TA, and Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. (1999) 143:205–11. doi: 10.1016/S0021-9150(98)00318-9
25. Doring Y, van der Vorst EPC, and Weber C. Targeting immune cell recruitment in atherosclerosis. Nat Rev Cardiol. (2024) 21:824–40. doi: 10.1038/s41569-024-01023-z
26. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation. (2004) 109:380–5.
27. Yan M, Zhong Y, Ni S, Zhang S, Jiang Y, Zhu L, et al. CCR2-engineered macrophage membrane-coated metal-polyphenol nanozyme to enhance antioxidation activity for inhibiting the atherosclerotic progression. Adv Healthc Mater. (2025):e02151.
28. de Jager SC, Bot I, Kraaijeveld AO, Korporaal SJ, Bot M, van Santbrink PJ, et al. Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. Arterioscler Thromb Vasc Biol. (2013) 33:e75–83. doi: 10.1161/ATVBAHA.112.300857
29. Chang TT, Yang HY, Chen C, and Chen JW. CCL4 inhibition in atherosclerosis: effects on plaque stability, endothelial cell adhesiveness, and macrophages activation. Int J Mol Sci. (2020) 21. doi: 10.3390/ijms21186567
30. Weber C, Weber KS, Klier C, Gu S, Wank R, Horuk R, et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood. (2001) 97:1144–6. doi: 10.1182/blood.V97.4.1144
31. Jongstra-Bilen J, Tai K, Althagafi MG, Siu A, Scipione CA, Karim S, et al. Role of myeloid-derived chemokine CCL5/RANTES at an early stage of atherosclerosis. J Mol Cell Cardiol. (2021) 156:69–78. doi: 10.1016/j.yjmcc.2021.03.010
32. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. (2011) 13:592–600. doi: 10.1016/j.cmet.2011.02.016
33. Soehnlein O, Drechsler M, Döring Y, Lievens D, Hartwig H, Kemmerich K, et al. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med. (2013) 5:471–81. doi: 10.1002/emmm.201201717
34. Lundahl J, Sköld CM, Halldén G, Hallgren M, and Eklund A. Monocyte and neutrophil adhesion to matrix proteins is selectively enhanced in the presence of inflammatory mediators. Scand J Immunol. (1996) 44:143–9. doi: 10.1046/j.1365-3083.1996.d01-296.x
35. Zernecke A, Weber KS, Erwig LP, Kluth DC, Schröppel B, Rees AJ, et al. Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol. (2001) 166:5755–62. doi: 10.4049/jimmunol.166.9.5755
36. Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LK, et al. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol. (2006) 168:1385–95. doi: 10.2353/ajpath.2006.040748
37. Kim SM, Lee CW, Kim BY, Jung YS, Eo SK, Park YC, et al. 27-Oxygenated cholesterol induces expression of CXCL8 in macrophages via NF-kappaB and CD88. Biochem Biophys Res Commun. (2015) 463:1152–8. doi: 10.1016/j.bbrc.2015.06.075
38. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. (2003) 107:1009–16.
39. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. (2007) 117:185–94. doi: 10.1172/JCI28549
40. Chen S, Shimada K, Zhang W, Huang G, Crother TR, and Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J Immunol. (2010) 185:5619–27. doi: 10.4049/jimmunol.1001879
41. Haidari M, Wyde PR, Litovsky S, Vela D, Ali M, Casscells SW, et al. Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice. Atherosclerosis. (2010) 208:90–6.
42. DeVito L, Mohanraj OS, Debnath D, Constantinesco NJ, Chinnappan B, Srikanth S, et al. Influenza infection exacerbates high-fat diet-induced atherosclerosis in apolipoprotein gene-deficient mice. J Immunol. (2025). doi: 10.1093/jimmun/vkaf276
43. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. (2010) 10:36–46. doi: 10.1038/nri2675
44. Tabas I and Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. (2011) 13:184–90. doi: 10.1038/ncb0311-184
45. Virmani R, Burke AP, Kolodgie FD, and Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol. (2002) 15:439–46. doi: 10.1111/j.1540-8183.2002.tb01087.x
46. van der Vorst EPC, Doring Y, and Weber C. Chemokines and their receptors in Atherosclerosis. J Mol Med. (2015) 93:963–71. doi: 10.1007/s00109-015-1317-8
47. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. (2009) 113:963–72.
48. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, and Luster AD. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res. (2000) 86:131–8. doi: 10.1161/01.RES.86.2.131
49. Singh A, Kraaijeveld AO, Curaj A, Wichapong K, Hammerich L, de Jager SCA, et al. CCL18 aggravates atherosclerosis by inducing CCR6-dependent T-cell influx and polarization. Front Immunol. (2024) 15:1327051. doi: 10.3389/fimmu.2024.1327051
50. Segers D, Lipton JA, Leenen PJ, Cheng C, Tempel D, Pasterkamp G, et al. Atherosclerotic plaque stability is affected by the chemokine CXCL10 in both mice and humans. Int J Inflam. (2011) 2011:936109. doi: 10.4061/2011/936109
51. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation. (2006) 113:2301–12.
52. Plonski A, Krupa A, Plonski AF, Pawlak D, Gabriel M, Sieklucka B, et al. Obesity-related serum monocyte chemoattractant protein-1 (MCP-1) as a biomarker of plaque instability in patients undergoing carotid endarterectomy. Int J Mol Sci. (2025) 26.
53. Abi-Younes S, Si-Tahar M, and Luster AD. The CC chemokines MDC and TARC induce platelet activation via CCR4. Thromb Res. (2001) 101:279–89. doi: 10.1016/S0049-3848(00)00402-3
54. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res. (2005) 96:612–6. doi: 10.1161/01.RES.0000160077.17427.57
55. Kraemer BF, Borst O, Gehring EM, Schoenberger T, Urban B, Ninci E, et al. PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1). J Mol Med (Berl). (2010) 88:1277–88. doi: 10.1007/s00109-010-0680-8
56. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A. (2006) 103:3781–6. doi: 10.1073/pnas.0511043103
57. Herlea-Pana O, Yao L, Heuser-Baker J, Wang Q, Wang Q, Georgescu C, et al. Chemokine receptors CXCR2 and CX3CR1 differentially regulate functional responses of bone-marrow endothelial progenitors during atherosclerotic plaque regression. Cardiovasc Res. (2015) 106:324–37. doi: 10.1093/cvr/cvv111
58. Li J, Zhang Y, Guo X, Wu Y, Huang R, and Han X. Circulating level of monocyte chemoattractant protein-1 and risk of coronary artery disease: A case-control and mendelian randomization study. Pharmgenomics Pers Med. (2021) 14:553–9. doi: 10.2147/PGPM.S303362
59. Yan Y, Thakur M, van der Vorst EPC, Weber C, and Doring Y. Targeting the chemokine network in atherosclerosis. Atherosclerosis. (2021) 330:95–106.
60. Dusi V, Ghidoni A, Ravera A, De Ferrari GM, and Calvillo L. Chemokines and heart disease: A network connecting cardiovascular biology to immune and autonomic nervous systems. Mediators Inflamm. (2016) 2016:5902947. doi: 10.1155/2016/5902947
61. Gencer S, Evans BR, van der Vorst EPC, Doring Y, and Weber C. Inflammatory chemokines in atherosclerosis. Cells. (2021) 10. doi: 10.3390/cells10020226
62. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, and Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol. (2006) 26:194–9. doi: 10.1161/01.ATV.0000191633.52585.14
63. Luciano-Mateo F, Cabre N, Fernandez-Arroyo S, Baiges-Gaya G, Hernandez-Aguilera A, Rodriguez-Tomas E, et al. Chemokine C-C motif ligand 2 overexpression drives tissue-specific metabolic responses in the liver and muscle of mice. Sci Rep. (2020) 10:11954. doi: 10.1038/s41598-020-68769-7
64. Ting KH, Ueng KC, Chiang WL, Chou YE, Yang SF, and Wang PH. Relationship of genetic polymorphisms of the chemokine, CCL5, and its receptor, CCR5, with coronary artery disease in Taiwan. Evid Based Complement Alternat Med. (2015) 2015:851683. doi: 10.1155/2015/851683
65. Breland UM, Halvorsen B, Hol J, Oie E, Paulsson-Berne G, Yndestad A, et al. A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol. (2008) 28:1005–11. doi: 10.1161/ATVBAHA.108.162305
66. Sjaarda J, Gerstein H, Chong M, Yusuf S, Meyre D, Anand SS, et al. Blood CSF1 and CXCL12 as causal mediators of coronary artery disease. J Am Coll Cardiol. (2018) 72:300–10. doi: 10.1016/j.jacc.2018.04.067
67. Fang N, Jiang M, and Fan Y. Ideal cardiovascular health metrics and risk of cardiovascular disease or mortality: A meta-analysis. Int J Cardiol. (2016) 214:279–83. doi: 10.1016/j.ijcard.2016.03.210
68. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. (2013) 309:1268–77. doi: 10.1001/jama.2013.2024
69. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. (2009) 301:383–92. doi: 10.1001/jama.2009.2
70. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. (2011) 365:32–43. doi: 10.1056/NEJMoa1100171
71. Shioi T, Matsumori A, Kihara Y, Inoko M, Ono K, Iwanaga Y, et al. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res. (1997) 81:664–71. doi: 10.1161/01.RES.81.5.664
72. Behr TM, Wang X, Aiyar N, Coatney RW, Li X, Koster P, et al. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation. (2000) 102:1315–22.
73. Stumpf C, Lehner C, Raaz D, Yilmaz A, Anger T, Daniel WG, et al. Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure. Heart. (2008) 94:65–9. doi: 10.1136/hrt.2007.115006
74. Montecucco F, Braunersreuther V, Lenglet S, Delattre BM, Pelli G, Buatois V, et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J. (2012) 33:1964–74. doi: 10.1093/eurheartj/ehr127
75. Wei J, Yu P, Hu Y, Qiao L, Li B, Li H, et al. CLU, FOS, and CXCL8 as diagnostic biomarkers for heart failure progression post-acute myocardial infarction: an integrated RNA-Seq and multi-machine learning study. Front Cardiovasc Med. (2025) 12:1611668. doi: 10.3389/fcvm.2025.1611668
76. Amara M, Stoler O, and Birati EY. The role of inflammation in the pathophysiology of heart failure. Cells. (2025) 14. doi: 10.3390/cells14141117
77. Gremese E, Bruno D, Perniola S, Ceolan J, and Ferraccioli G. Autoimmune inflammation as a key risk factor for heart failure with preserved ejection fraction: the different types of inflammation driving to HFpEF. Front Med (Lausanne). (2025) 12:1557312. doi: 10.3389/fmed.2025.1557312
78. Liu H, Magaye R, Kaye DM, and Wang BH. Heart failure with preserved ejection fraction: The role of inflammation. Eur J Pharmacol. (2024) 980:176858. doi: 10.1016/j.ejphar.2024.176858
79. Damås JK, Gullestad L, Ueland T, Solum NO, Simonsen S, Frøland SS, et al. CXC-chemokines, a new group of cytokines in congestive heart failure–possible role of platelets and monocytes. Cardiovasc Res. (2000) 45:428–36.
80. Satoh M, Akatsu T, Ishkawa Y, Minami Y, and Nakamura M. A novel activator of C-C chemokine, FROUNT, is expressed with C-C chemokine receptor 2 and its ligand in failing human heart. J Card Fail. (2007) 13:114–9. doi: 10.1016/j.cardfail.2006.11.003
81. Frangogiannis NG, Dewald O, Xia Y, Ren G, Haudek S, Leucker T, et al. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation. (2007) 115:584–92.
82. Aukrust P, Ueland T, Müller F, Andreassen AK, Nordøy I, Aas H, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. (1998) 97:1136–43.
83. Hohensinner PJ, Rychli K, Zorn G, Hülsmann M, Berger R, Mörtl D, et al. Macrophage-modulating cytokines predict adverse outcome in heart failure. Thromb Haemost. (2010) 103:435–41. doi: 10.1160/TH09-06-0399
84. Braunersreuther V, Pellieux C, Pelli G, Burger F, Steffens S, Montessuit C, et al. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol. (2010) 48:789–98. doi: 10.1016/j.yjmcc.2009.07.029
85. Komuro J, Hashimoto H, Katsuki T, Kusumoto D, Katoh M, Ko T, et al. Heart failure-specific cardiac fibroblasts contribute to cardiac dysfunction via the MYC-CXCL1-CXCR2 axis. Nat Cardiovasc Res. (2025) 4:1135–51. doi: 10.1038/s44161-025-00698-y
86. Kumowski N, Pabel S, Grune J, Momin N, Ninh VK, Stengel L, et al. Resistin-like molecule gamma attacks cardiomyocyte membranes and promotes ventricular tachycardia. Science. (2025) 389:1043–8.
87. Wu N, Xu B, Xiang Y, Wu L, Zhang Y, Ma X, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int J Cardiol. (2013) 169:62–72. doi: 10.1016/j.ijcard.2013.08.078
88. Davatelis G, Wolpe SD, Sherry B, Dayer JM, Chicheportiche R, and Cerami A. Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. Science. (1989) 243:1066–8. doi: 10.1126/science.2646711
89. Elmas E, Lang S, Dempfle CE, Kälsch T, Hannak D, Sueselbeck T, et al. High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction. Clin Chem Lab Med. (2007) 45:1360–5. doi: 10.1515/CCLM.2007.286
90. Asimaki A, Tandri H, Duffy ER, Winterfield JR, Mackey-Bojack S, Picken MM, et al. Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. (2011) 4:743–52. doi: 10.1161/CIRCEP.111.964890
91. Liuba I, Ahlmroth H, Jonasson L, Englund A, Jönsson A, Säfström K, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace. (2008) 10:848–53.
92. Scicluna BP, Remme CA, Rivaud M, Wilde AA, Bezzina CR, and Verkerk AO. Chemokine ligand 9 modulates cardiac repolarization via Cxcr3 receptor binding. Int J Cardiol. (2015) 201:49–52. doi: 10.1016/j.ijcard.2015.07.096
93. Zhang YL, Cao HJ, Han X, Teng F, Chen C, Yang J, et al. Chemokine receptor CXCR-2 initiates atrial fibrillation by triggering monocyte mobilization in mice. Hypertension. (2020) 76:381–92.
94. Golpour A, Patriki D, Hanson PJ, McManus B, and Heidecker B. Epidemiological impact of myocarditis. J Clin Med. (2021) 10. doi: 10.3390/jcm10040603
95. Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. (2021) 18:169–93. doi: 10.1038/s41569-020-00435-x
96. Mann DL, Topkara VK, Evans S, and Barger PM. Innate immunity in the adult mammalian heart: for whom the cell tolls. Trans Am Clin Climatol Assoc. (2010) 121:34–50.
97. Madjid M, Naghavi M, Litovsky S, and Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation. (2003) 108:2730–6. doi: 10.1161/01.CIR.0000102380.47012.92
98. Kishimoto C, Kawamata H, Sakai S, Shinohara H, and Ochiai H. Role of MIP-2 in coxsackievirus B3 myocarditis. J Mol Cell Cardiol. (2000) 32:631–8. doi: 10.1006/jmcc.2000.1102
99. Constantinesco NJ, Srikanth S, De Vito L, Moras C, Ramasubramanian V, Chinnappan B, et al. STAT1 regulates neutrophil gelatinase B-associated lipocalin induction in influenza-induced myocarditis. Sci Rep. (2024) 14:11124. doi: 10.1038/s41598-024-61953-z
100. Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J. (2017) 38:2649–62. doi: 10.1093/eurheartj/ehx321
101. Bracamonte-Baran W and Cihakova D. Cardiac autoimmunity: myocarditis. Adv Exp Med Biol. (2017) 1003:187–221.
102. Goser S, Ottl R, Brodner A, Dengler TJ, Torzewski J, Egashira K, et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation. (2005) 112:3400–7.
103. Jenke A, Wilk S, Poller W, Eriksson U, Valaperti A, Rauch BH, et al. Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury. Cardiovasc Res. (2013) 99:422–31. doi: 10.1093/cvr/cvt118
104. Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, et al. Silencing of CCR2 in myocarditis. Eur Heart J. (2015) 36:1478–88. doi: 10.1093/eurheartj/ehu225
105. Feng G, Zhu C, Lin CY, Bredemeyer A, Forster I, Kreisel D, et al. CCL17 protects against viral myocarditis by suppressing the recruitment of regulatory T cells. J Am Heart Assoc. (2023) 12:e028442. doi: 10.1161/JAHA.122.028442
106. Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. (2011) 107:906–11. doi: 10.1016/j.amjcard.2010.11.005
107. Zivkovic L, Asare Y, Bernhagen J, Dichgans M, and Georgakis MK. Pharmacological targeting of the CCL2/CCR2 axis for atheroprotection: A meta-analysis of preclinical studies. Arterioscler Thromb Vasc Biol. (2022) 42:e131–e44.
108. Colombo A, Basavarajaiah S, Limbruno U, Picchi A, Lettieri C, Valgimigli M, et al. A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. EuroIntervention. (2016) 12:e1385–e94. doi: 10.4244/EIJY15M12_03
109. Noels H, Weber C, and Koenen RR. Chemokines as therapeutic targets in cardiovascular disease. Arterioscler Thromb Vasc Biol. (2019) 39:583–92. doi: 10.1161/ATVBAHA.118.312037
110. Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D’Amore C, et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation. (2013) 127:2114–24.
111. Chung ES, Miller L, Patel AN, Anderson RD, Mendelsohn FO, Traverse J, et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial. Eur Heart J. (2015) 36:2228–38. doi: 10.1093/eurheartj/ehv254
112. Sallusto F and Mackay CR. Chemoattractants and their receptors in homeostasis and inflammation. Curr Opin Immunol. (2004) 16:724–31. doi: 10.1016/j.coi.2004.09.012
113. Cui LY, Chu SF, and Chen NH. The role of chemokines and chemokine receptors in multiple sclerosis. Int Immunopharmacol. (2020) 83:106314. doi: 10.1016/j.intimp.2020.106314
114. Hughes CE and Nibbs RJB. A guide to chemokines and their receptors. FEBS J. (2018) 285:2944–71. doi: 10.1111/febs.14466
115. Pease JE and Williams TJ. Chemokines and their receptors in allergic disease. J Allergy Clin Immun. (2006) 118:305–18. doi: 10.1016/j.jaci.2006.06.010
116. Ness TL, Ewing JL, Hogaboam CM, and Kunkel SL. CCR4 is a key modulator of innate immune responses. J Immunol. (2006) 177:7531–9. doi: 10.4049/jimmunol.177.11.7531
117. Lin YT, Liu SS, Sun Y, Chen C, Yang SW, Pei G, et al. CCR5 and inflammatory storm. Ageing Res Rev. (2024) 96. doi: 10.1016/j.arr.2024.102286
118. Jasinska AJ, Pandrea I, and Apetrei C. CCR5 as a coreceptor for human immunodeficiency virus and simian immunodeficiency viruses: A prototypic love-hate affair. Front Immunol. (2022) 13. doi: 10.3389/fimmu.2022.835994
119. Shi ZR, Mabuchi T, Riutta SJ, Wu X, Peterson FC, Volkman BF, et al. The chemokine, CCL20, and its receptor, CCR6, in the pathogenesis and treatment of psoriasis and psoriatic arthritis. J Psoriasis Psoriatic Arthritis. (2023) 8:107–17. doi: 10.1177/24755303231159106
120. Förster R, Davalos-Misslitz AC, and Rot A. CCR7 and its ligands:: balancing immunity and tolerance. Nat Rev Immunol. (2008) 8:362–71.
121. Kim N, Kim MH, Pyo J, Lee SM, Jang JS, Lee DW, et al. CCR8 as a therapeutic novel target: omics-integrated comprehensive analysis for systematically prioritizing indications. Biomedicines. (2023) 11. doi: 10.3390/biomedicines11112910
122. Pathak M and Lal G. The regulatory function of CCR9(+) dendritic cells in inflammation and autoimmunity. Front Immunol. (2020) 11:536326. doi: 10.3389/fimmu.2020.536326
123. Willuveit AL, Stefanini ACB, Matozo T, and Marti LC. CCR10: a comprehensive review of its function, phylogeny, role in immune cell trafficking and disease pathogenesis. Front Immunol. (2025) 16:1599277. doi: 10.3389/fimmu.2025.1599277
124. Ishimoto N, Park JH, Kawakami K, Tajiri M, Mizutani K, Akashi S, et al. Structural basis of CXC chemokine receptor 1 ligand binding and activation. Nat Commun. (2023) 14. doi: 10.1038/s41467-023-39799-2
125. Veenstra M and Ransohoff RM. Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller? J Neuroimmunol. (2012) 246:1–9. doi: 10.1016/j.jneuroim.2012.02.016
126. Groom JR and Luster AD. CXCR3 in T cell function. Exp Cell Res. (2011) 317:620–31. doi: 10.1016/j.yexcr.2010.12.017
127. Colvin RA, Campanella GS, Sun J, and Luster AD. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem. (2004) 279:30219–27. doi: 10.1074/jbc.M403595200
128. Bianchi ME and Mezzapelle R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration. Front Immunol. (2020) 11:2109. doi: 10.3389/fimmu.2020.02109
129. Moser B. CXCR5, the defining marker for follicular B helper T (T) cells. Front Immunol. (2015) 6. doi: 10.3389/fimmu.2015.00296
130. Slight SR, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko BA, Mehra S, et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. J Clin Invest. (2013) 123:712–26. doi: 10.1172/JCI65728
131. Mabrouk N, Tran T, Sam I, Pourmir I, Gruel N, Granier C, et al. CXCR6 expressing T cells: Functions and role in the control of tumors. Front Immunol. (2022) 13. doi: 10.3389/fimmu.2022.1022136
132. Wein AN, McMaster SR, Takamura S, Dunbar PR, Cartwright EK, Hayward SL, et al. CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways. J Exp Med. (2019) 216:2748–62. doi: 10.1084/jem.20181308
133. Yu S, Crawford D, Tsuchihashi T, Behrens TW, and Srivastava D. The chemokine receptor CXCR7 functions to regulate cardiac valve remodeling. Dev Dyn. (2011) 240:384–93. doi: 10.1002/dvdy.22549
134. Lin L, Han MM, Wang F, Xu LL, Yu HX, and Yang PY. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. Cell Death Dis. (2014) 5:e1488. doi: 10.1038/cddis.2014.392
135. Kroczek RA and Henn V. The role of XCR1 and its ligand XCL1 in antigen cross-presentation by murine and human dendritic cells. Front Immunol. (2012) 3:14. doi: 10.3389/fimmu.2012.00014
136. Horuk R. The duffy antigen receptor for chemokines DARC/ACKR1. Front Immunol. (2015) 6:279. doi: 10.3389/fimmu.2015.00279
137. Jinna N, Rida P, Su T, Gong Z, Yao S, LaBarge M, et al. The DARC side of inflamm-aging: duffy antigen receptor for chemokines (DARC/ACKR1) as a potential biomarker of aging, immunosenescence, and breast oncogenesis among high-risk subpopulations. Cells. (2022) 11. doi: 10.3390/cells11233818
Keywords: arrhythmia, atherosclerosis, chemokines, coronary artery disease, heart failure, myocarditis
Citation: Srikanth S, DeVito L, Constantinesco NJ and Gopal R (2026) The role of chemokines and their receptors in cardiovascular diseases. Front. Immunol. 17:1758588. doi: 10.3389/fimmu.2026.1758588
Received: 01 December 2025; Accepted: 15 January 2026; Revised: 14 January 2026;
Published: 04 February 2026.
Edited by:
Markus Bosmann, Boston University, United StatesReviewed by:
Michael Molitor, Johannes Gutenberg University Mainz, GermanyCopyright © 2026 Srikanth, DeVito, Constantinesco and Gopal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Radha Gopal, cmFnMTAwQHBpdHQuZWR1